ATE238794T1 - Verwendung von einem draflazin analog zur schmerzbehandlung - Google Patents
Verwendung von einem draflazin analog zur schmerzbehandlungInfo
- Publication number
- ATE238794T1 ATE238794T1 AT98934969T AT98934969T ATE238794T1 AT E238794 T1 ATE238794 T1 AT E238794T1 AT 98934969 T AT98934969 T AT 98934969T AT 98934969 T AT98934969 T AT 98934969T AT E238794 T1 ATE238794 T1 AT E238794T1
- Authority
- AT
- Austria
- Prior art keywords
- phenyl
- draflazine
- analog
- derivative
- 4alkyl
- Prior art date
Links
- IWMYIWLIESDFRZ-UHFFFAOYSA-N 1-[2-(4-amino-2,6-dichloroanilino)-2-oxoethyl]-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide Chemical class C1CN(CC(=O)NC=2C(=CC(N)=CC=2Cl)Cl)C(C(=O)N)CN1CCCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 IWMYIWLIESDFRZ-UHFFFAOYSA-N 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97201813 | 1997-06-16 | ||
| PCT/EP1998/003664 WO1998057643A1 (en) | 1997-06-16 | 1998-06-09 | Use of draflazine-analogues for treating pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE238794T1 true ATE238794T1 (de) | 2003-05-15 |
Family
ID=8228446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98934969T ATE238794T1 (de) | 1997-06-16 | 1998-06-09 | Verwendung von einem draflazin analog zur schmerzbehandlung |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6403589B1 (de) |
| EP (1) | EP0999840B1 (de) |
| JP (1) | JP2002504134A (de) |
| KR (1) | KR20010013387A (de) |
| AT (1) | ATE238794T1 (de) |
| AU (1) | AU8438798A (de) |
| CA (1) | CA2294011A1 (de) |
| DE (1) | DE69814089T2 (de) |
| ES (1) | ES2199447T3 (de) |
| WO (1) | WO1998057643A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001046166A2 (en) * | 1999-12-20 | 2001-06-28 | Neuromed Technologies, Inc. | Partially saturated calcium channel blockers |
| SI1539124T1 (sl) | 2002-09-05 | 2018-12-31 | Vanderbilt Royalty Sub L.P. | Sestavki in kompleti za odstranjevanje dražilnih spojin s telesnih površin |
| WO2004101593A1 (ja) * | 2003-05-16 | 2004-11-25 | Kissei Pharmaceutical Co., Ltd. | ５’−修飾ヌクレオシド誘導体及びその医薬用途 |
| DE602006017345D1 (de) * | 2005-04-01 | 2010-11-18 | Neurogesx Inc | Öle von capsaicinoiden und verfahren zu ihrer herstellung und verwendung |
| WO2011000945A2 (en) | 2009-07-03 | 2011-01-06 | Nensius Research A/S | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns |
| PE20161476A1 (es) | 2014-06-26 | 2017-01-07 | Hoffmann La Roche | Derivados de indolin-2-ona o pirrolo-piridin-2-ona |
| JP6857653B2 (ja) | 2015-11-06 | 2021-04-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体 |
| RU2727179C2 (ru) | 2015-11-06 | 2020-07-21 | Ф. Хоффманн-Ля Рош Аг | Производные индолин-2-она |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2368280A1 (fr) * | 1976-10-20 | 1978-05-19 | Theramex | Nouvelle composition therapeutique presentant une activite anti-agregante plaquettaire, et son procede de preparation |
| US4766125A (en) | 1981-06-23 | 1988-08-23 | Janssen Pharmaceutica N.V. | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia |
| FR2513118A1 (fr) * | 1981-09-18 | 1983-03-25 | Rocador Sa | Composition pharmaceutique a base de dipyridamol et de sel d'aluminium de l'acide acetylsalicylique pour combattre l'agregation plaquettaire |
| NZ223847A (en) * | 1987-04-01 | 1989-12-21 | Janssen Pharmaceutica Nv | Substituted piperazine derivatives and pharmaceutical compositions |
| US5236908A (en) | 1991-06-07 | 1993-08-17 | Gensia Pharmaceuticals, Inc. | Methods of treating injury to the central nervous system |
| IL108524A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Imidazodiazepine analogs |
-
1998
- 1998-06-09 ES ES98934969T patent/ES2199447T3/es not_active Expired - Lifetime
- 1998-06-09 AU AU84387/98A patent/AU8438798A/en not_active Abandoned
- 1998-06-09 AT AT98934969T patent/ATE238794T1/de not_active IP Right Cessation
- 1998-06-09 JP JP50374399A patent/JP2002504134A/ja not_active Withdrawn
- 1998-06-09 US US09/446,140 patent/US6403589B1/en not_active Expired - Lifetime
- 1998-06-09 CA CA002294011A patent/CA2294011A1/en not_active Abandoned
- 1998-06-09 WO PCT/EP1998/003664 patent/WO1998057643A1/en not_active Ceased
- 1998-06-09 DE DE69814089T patent/DE69814089T2/de not_active Expired - Fee Related
- 1998-06-09 KR KR19997011386A patent/KR20010013387A/ko not_active Ceased
- 1998-06-09 EP EP98934969A patent/EP0999840B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69814089T2 (de) | 2004-02-19 |
| EP0999840A1 (de) | 2000-05-17 |
| KR20010013387A (ko) | 2001-02-26 |
| US6403589B1 (en) | 2002-06-11 |
| JP2002504134A (ja) | 2002-02-05 |
| AU8438798A (en) | 1999-01-04 |
| EP0999840B1 (de) | 2003-05-02 |
| DE69814089D1 (de) | 2003-06-05 |
| ES2199447T3 (es) | 2004-02-16 |
| CA2294011A1 (en) | 1998-12-23 |
| WO1998057643A1 (en) | 1998-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL110031A0 (en) | Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them | |
| BG106867A (en) | Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases | |
| BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
| ATE538794T1 (de) | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer | |
| FI935778A7 (fi) | HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten | |
| MY128664A (en) | Crystal modification of a n-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use | |
| CY1108813T1 (el) | Αναστολεις κινασων τυροσινης | |
| ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
| NO971889L (no) | Forbindelser og sammensetninger for levering av aktive midler | |
| PT705100E (pt) | Guanidinas substituidas terapeuticas | |
| IL132608A0 (en) | Fused dihydropyran compounds medicaments containing the same and the use thereof | |
| NO990662L (no) | Trombin-inhibitorer | |
| IN2005KO00312A (de) | ||
| FI935780A7 (fi) | HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten | |
| ATE238794T1 (de) | Verwendung von einem draflazin analog zur schmerzbehandlung | |
| DE69918972D1 (de) | Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE265455T1 (de) | Tetrahydropyridoverbindungen | |
| FI935779A7 (fi) | HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten | |
| ES2088128T3 (es) | Aminosulfonilureas inhibidoras de acat. | |
| GB9907571D0 (en) | Compounds | |
| ATE332688T1 (de) | Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung | |
| ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
| PL336897A1 (en) | Novel salts of bpc peptides, pharmaceutic compositions conatining them and method of obtaining such salts | |
| DE60010934D1 (de) | Medikamente geeignet zur Behandlung von proliferativen Erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |